Literature DB >> 2622331

Mycoplasma pulmonis V-1 surface protein variation: occurrence in vivo and association with lung lesions.

D F Talkington1, M T Fallon, H L Watson, R K Thorp, G H Cassell.   

Abstract

The V-1 antigen of Mycoplasma pulmonis is exposed to the surface of the mycoplasma and has an immunoblot banding pattern that varies in vitro between and within strains. To determine if V-1 variation occurs in vivo, we infected C3H/HeNCr mice intranasally with 5 X 10(8) colony-forming units of M. pulmonis strain 5782C. We isolated M. pulmonis clones from the respiratory tracts of mice up to 28 days post-infection, then used anti-V-1 monoclonal antibody P39 to visualize their V-1 immunoblot banding patterns. By the 28th day following infection, 92% of the recovered clones had variant V-1 banding patterns. Additionally, there was a significant correlation between the severity of lung lesions and the percentage of V-1 variant clones recovered from the respiratory tracts of individual mice. These studies prove that V-1 variation does occur in vivo, and suggest that mice with more severe pulmonary lesions tend to have more V-1 variant clones as a percentage of the M. pulmonis population. Thus, variation in the V-1 protein may be a mechanism by which M. pulmonis persists in the in vivo environment, possibly by evasion of host immune surveillance or by alteration of its surface membrane to take better advantage of its environmental niche in the host.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2622331     DOI: 10.1016/0882-4010(89)90023-5

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  11 in total

1.  Gene rearrangements in the vsa locus of Mycoplasma pulmonis.

Authors:  X Shen; J Gumulak; H Yu; C T French; N Zou; K Dybvig
Journal:  J Bacteriol       Date:  2000-05       Impact factor: 3.490

2.  Serotype diversity and antigen variation among invasive isolates of Ureaplasma urealyticum from neonates.

Authors:  X Zheng; H L Watson; K B Waites; G H Cassell
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

3.  A family of phase-variable restriction enzymes with differing specificities generated by high-frequency gene rearrangements.

Authors:  K Dybvig; R Sitaraman; C T French
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

4.  A stochastic mechanism for biofilm formation by Mycoplasma pulmonis.

Authors:  Warren L Simmons; Jeffrey R Bolland; James M Daubenspeck; Kevin Dybvig
Journal:  J Bacteriol       Date:  2006-12-01       Impact factor: 3.490

5.  Ciliostasis and loss of cilia induced by Mycoplasma hyopneumoniae in porcine tracheal organ cultures.

Authors:  M C DeBey; R F Ross
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

6.  Variable antigens of Ureaplasma urealyticum containing both serovar-specific and serovar-cross-reactive epitopes.

Authors:  H L Watson; D K Blalock; G H Cassell
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

7.  The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.

Authors:  Warren L Simmons; Kevin Dybvig
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

Review 8.  Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns.

Authors:  G H Cassell; K B Waites; H L Watson; D T Crouse; R Harasawa
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

9.  Antigen heterogeneity among isolates of Mycoplasma bovis is generated by high-frequency variation of diverse membrane surface proteins.

Authors:  R Rosengarten; A Behrens; A Stetefeld; M Heller; M Ahrens; K Sachse; D Yogev; H Kirchhoff
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Sequence analysis of the chromosomal region around and within the V-1-encoding gene of Mycoplasma pulmonis: evidence for DNA inversion as a mechanism for V-1 variation.

Authors:  W L Simmons; C Zuhua; J I Glass; J W Simecka; G H Cassell; H L Watson
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.